EP4466282A4 - Rezeptoren zur gezielten costimulation für adoptive zelltherapie - Google Patents

Rezeptoren zur gezielten costimulation für adoptive zelltherapie

Info

Publication number
EP4466282A4
EP4466282A4 EP23743925.2A EP23743925A EP4466282A4 EP 4466282 A4 EP4466282 A4 EP 4466282A4 EP 23743925 A EP23743925 A EP 23743925A EP 4466282 A4 EP4466282 A4 EP 4466282A4
Authority
EP
European Patent Office
Prior art keywords
receptors
cell therapy
adoptive cell
costimulation
targeted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP23743925.2A
Other languages
English (en)
French (fr)
Other versions
EP4466282A2 (de
Inventor
John Bridgeman
Robert Hawkins
Ruben Rodriguez
Gray Kueberuwa
Milena Kalaitsidou
Michael Gavin King
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Instil Bio Inc
Original Assignee
Instil Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US17/807,109 external-priority patent/US11945876B2/en
Application filed by Instil Bio Inc filed Critical Instil Bio Inc
Publication of EP4466282A2 publication Critical patent/EP4466282A2/de
Publication of EP4466282A4 publication Critical patent/EP4466282A4/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4224—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4264—Cancer antigens from embryonic or fetal origin
    • A61K40/4266—Carcinoembryonic antigen [CEA]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/104—Aminoacyltransferases (2.3.2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/27—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by targeting or presenting multiple antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/27—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by targeting or presenting multiple antigens
    • A61K2239/28—Expressing multiple CARs, TCRs or antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP23743925.2A 2022-01-20 2023-01-19 Rezeptoren zur gezielten costimulation für adoptive zelltherapie Pending EP4466282A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263301340P 2022-01-20 2022-01-20
US17/807,109 US11945876B2 (en) 2021-06-16 2022-06-15 Receptors providing targeted costimulation for adoptive cell therapy
PCT/US2023/060937 WO2023141530A2 (en) 2022-01-20 2023-01-19 Receptors providing targeted costimulation for adoptive cell therapy

Publications (2)

Publication Number Publication Date
EP4466282A2 EP4466282A2 (de) 2024-11-27
EP4466282A4 true EP4466282A4 (de) 2026-02-11

Family

ID=87349137

Family Applications (1)

Application Number Title Priority Date Filing Date
EP23743925.2A Pending EP4466282A4 (de) 2022-01-20 2023-01-19 Rezeptoren zur gezielten costimulation für adoptive zelltherapie

Country Status (7)

Country Link
EP (1) EP4466282A4 (de)
JP (1) JP2025508319A (de)
KR (1) KR20240145092A (de)
CN (1) CN119384431A (de)
AU (1) AU2023209445A1 (de)
CA (1) CA3249157A1 (de)
WO (1) WO2023141530A2 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025160035A1 (en) * 2024-01-22 2025-07-31 Board Of Regents, The University Of Texas System Cell therapies for disrupting collagen and other ecm components
CN121270692B (zh) * 2025-12-05 2026-03-27 中国农业科学院都市农业研究所 猪流行性腹泻病毒特异性单克隆抗体、应用及试纸条

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997034473A1 (en) * 1996-03-21 1997-09-25 The Trustees Of Columbia University In The City Of New York Craf1 (traf-3) isoforms and uses thereof
WO2022266192A1 (en) * 2021-06-16 2022-12-22 Instil Bio, Inc. Receptors providing targeted costimulation for adoptive cell therapy

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002098458A1 (en) * 2001-06-07 2002-12-12 Medvet Science Pty Ltd Sphingosine kinase interacts with traf2 and modulates tumor necrosis factor-induced cellular activity
US9486498B2 (en) * 2008-05-19 2016-11-08 Case Western Reserve University Method of treating CD40-mediated diseases
IL299886A (en) * 2020-07-17 2023-03-01 Instil Bio Uk Ltd Receptors that provide targeted costimulation for host cell therapy

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997034473A1 (en) * 1996-03-21 1997-09-25 The Trustees Of Columbia University In The City Of New York Craf1 (traf-3) isoforms and uses thereof
WO2022266192A1 (en) * 2021-06-16 2022-12-22 Instil Bio, Inc. Receptors providing targeted costimulation for adoptive cell therapy

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HAUER JULIA ET AL: "TNF receptor (TNFR)-associated factor (TRAF) 3 serves as an inhibitor of TRAF25-mediated activation of the noncanonical NF-B pathway by TRAF-binding TNFRs", PNAS, vol. 102, no. 8, 22 February 2005 (2005-02-22), pages 1 - 6, XP093325999 *
PULLEN S S ET AL: "CD40 signaling through tumor necrosis factor receptor-associated factors (TRAFs). Binding site specificity and activation of downstream pathways by distinct TRAFs", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, US, vol. 274, no. 20, 14 May 1999 (1999-05-14), pages 14246 - 14254, XP002301140, ISSN: 0021-9258, DOI: 10.1074/JBC.274.20.14246 *
PULLEN STEVEN S. ET AL: "High-Affinity Interactions of Tumor Necrosis Factor Receptor-Associated Factors (TRAFs) and CD40 Require TRAF Trimerization and CD40 Multimerization", BIOCHEMISTRY (EASTON), vol. 38, no. 31, 15 July 1999 (1999-07-15), United States, pages 10168 - 10177, XP093325950, ISSN: 0006-2960, DOI: 10.1021/bi9909905 *

Also Published As

Publication number Publication date
KR20240145092A (ko) 2024-10-04
CN119384431A (zh) 2025-01-28
AU2023209445A1 (en) 2024-08-01
JP2025508319A (ja) 2025-03-26
EP4466282A2 (de) 2024-11-27
CA3249157A1 (en) 2023-07-27
WO2023141530A2 (en) 2023-07-27
WO2023141530A3 (en) 2023-09-21

Similar Documents

Publication Publication Date Title
EP3914611C0 (de) Rezeptoren mit gezielter costimulierung für adoptive zelltherapie
IL299886A (en) Receptors that provide targeted costimulation for host cell therapy
EP4466282A4 (de) Rezeptoren zur gezielten costimulation für adoptive zelltherapie
CY1122664T1 (el) Θεραπεια για την προωθηση κυτταρικης αναπτυξης
EP3749740C0 (de) Systeme und verfahren für multiplexmessungen in einzel- und ensemble-zellen
MX2016006177A (es) Método para diseñar células t resistentes a fármacos de quimioterapia para inmunoterapia.
EP4413029A4 (de) Manipulierte cytokinrezeptoren für abstimmbare adoptive zelltherapie
EP4049188A4 (de) Flexibler beschleuniger für spärlichen tensoren in neuronalen faltungsnetzen
AR079889A1 (es) Antagonistas de wnt y metodos de tratamiento y deteccion
MX368000B (es) Composición de colágeno y ácido hialurónico para la reparación de ligamento o tendón.
EP4259105A4 (de) In-vivo-targeting von cd4+ -t-zellen für mrna-therapeutika
CR20130374A (es) Compuestos y métodos para la modulación de quinasas e indicaciones para los mismos
FR2931163B1 (fr) Lignee de cellules dendritiques plasmacytoides utilisee en therapie cellulaire active ou adoptive
EP4355340A4 (de) Rezeptoren zur gezielten costimulation für adoptive zelltherapie
BR112012031107A2 (pt) molécula de ligação específica cultivada contra a proteína anx-a1 humana, linha de células de hibridoma, composição farmacêutica , uso da molécula de ligação específica e método para o tratamento de uma doença mediada por linfócitos t em um indivíduo com necessidade do mesmo
ATE541211T1 (de) Verfahren zur beurteilung von zellen und zellkulturen
EP2277343A4 (de) Verfahren und system zur zellenneuauswahl zwischen frequenzen oder zwischen rat
EP4359541A4 (de) Manipulierte zellen für therapie
EP4502158A4 (de) Für cochlea- und/oder vestibuläre zellen spezifischer promotor und verwendung davon
EP4255501A4 (de) Verfahren zur erhöhung der therapeutischen wirksamkeit isolierter zellen für die zelltherapie
EP3926312A4 (de) Mikroskop für quantitative wellenfrontmessungen, mikroskopmodul und kit, verfahren und computerprogramm zur rechnerischen wellenfrontrekonstruktion
EP4473088A4 (de) Zelltherapie für diabetes
EP2571504A4 (de) Verwendung von aromatase-hemmern für synchronisierten eisprung, zur herbeiführung eines mehrfachen oder doppelten eisprungs sowie zur erhöhung der zwillingsbildung und der fruchtbarkeit von säugetieren
EP4551143A4 (de) Dermale lichtabgabevorrichtung für lichttherapie
EP4422598A4 (de) Designer-extrazellulare vesikel zur gezielten abgabe an schwann-zellen

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20240805

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: C07K0014715000

Ipc: A61K0035170000

A4 Supplementary search report drawn up and despatched

Effective date: 20260112

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 35/17 20150101AFI20260106BHEP

Ipc: C07K 14/705 20060101ALI20260106BHEP

Ipc: A61P 35/00 20060101ALI20260106BHEP

Ipc: C12N 5/0783 20100101ALI20260106BHEP

Ipc: A61K 40/11 20250101ALI20260106BHEP

Ipc: A61K 38/00 20060101ALI20260106BHEP

Ipc: A61K 40/31 20250101ALI20260106BHEP

Ipc: A61K 40/42 20250101ALI20260106BHEP

Ipc: C07K 14/725 20060101ALI20260106BHEP

Ipc: C07K 14/71 20060101ALI20260106BHEP

Ipc: C07K 16/30 20060101ALI20260106BHEP

Ipc: A61K 40/30 20250101ALI20260106BHEP

Ipc: C07K 14/715 20060101ALI20260106BHEP

Ipc: C12N 9/10 20060101ALI20260106BHEP